Login to Your Account

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance

By Jennifer Boggs

Wednesday, November 4, 2009

No Abstract


Assistant Managing Editor

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription